

Certificate of Analysis

BrSK2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-655, 14-655-K, 14-655M

Parent Lot # 28254U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, human BrSK2, amino acids 2–end, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 67% by SDS-PAGE and Coomassie blue staining. MW = 78.5kDa.

Specific Activity (Parent lot# 28254U): 197U/mg, where one unit of BrSK2 activity is defined as 1nmol phosphate incorporated into 500μM (KKLNRTLSFAEPG) per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 1.77mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: Stable for 6 months at -70°C from date of shipment. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 8–44ng of this lot of enzyme phosphorylated 500μM (KKLNRTLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as BrSK2 with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS-NaOH pH7.0, 1mM EDTA.
2. **(KKLNRTLSFAEPG):** Use at a final concentration of 500 μ M. Make a 5mM stock. Add 2.5 μ l of stock per assay point.
3. **BrSK2, active:** Dilute with 20mM MOPS-NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 8–44ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of 500 μ M **(KKLNRTLSFAEPG)**.
3. Add **2.5 μ l (8–44ng) BrSK2, active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

BrSK2 Sequence Information

<u>Protein</u>	Human BrSK2
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	T29 of the recombinant protein is equivalent to T2 of human BrSK2
<u>Accession number</u>	GenBank AF533878. The recombinant protein contains the amino acid substitution S251I with respect to AF533878. This conflict is reported in GenBank AF020086.

Recombinant BrSK2 amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMGSTS TGKDGGQAHA QYVGPIRLEK TLGKGQTGLV
61 KLGVHCVCVTCQ KVAIKIVNRE KLSESVLMKV EREIAILKLI EHPHVLKLHD VYENKKYLYL
121 VLEHVS GGEL FDYLVKKGRL TPKEARKFFR QIISALDFCH SHSICHRDLK PENLLLDEKN
181 NIRIADFGMA SLQVGDSLLE TSCGSPHYAC PEVIRGEKYD GRKADVWSCG VILFALLVGA
241 LPFDDDNLRQ LLEKVKRGVF HMPHFIPPDC QSLLRGMIEV DAARRLTLEH IQKHIWYIGG
301 KNEPEPEQPI PRKVQIRSLP SLEDIDPDVL DSMHSLGCFR DRNKLLQDLL SEEENQEKMI
361 YFLLLDLDRKER YPSQEDLDP PRNEIDPPRK RVDSPMLNRH GKRRPERKSM EVLSVTDGGS
421 PVPARRAIEM AQHGQSRISI SGASSGLSTS PLSSPRVTPH PSPRGSPLPT PKGTPVHTPK
481 ESPAGTPNPT PPSSPSVGGV PWRARLNSIK NSFLGSPRFH RRKLQVPTPE EMSNLTPESS
541 PELAKKSWFG NFISLEKEEQ IFVVIKDKPL SSIKADIVHA FLSIPSLSHS VISQTSFRAE
601 YKATGGPAVF QKPVKFQVDI TYTEGGEAQK ENGIYSVTFT LLSGPSRRFK RVVETIQAQL
661 LSTHDPPAAQ HLSEPPPPAP GLSWGAGLKG QKVATSYESS L

```

Recombinant BrSK2 nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcgccatggg atccacatcg acggggaagg acggcggcgc gcagcacgcg
121 cagtatgttg ggccctaccg gctggagaag acgctgggca aggggcagac aggtctggtg
181 aagctggggg ttactgctg cactgcccag aaggtggcca tcaagatcgt caaccgtgag
241 aagctcagcg agtcggtgct gatgaagggt gagcgggaga tcgcgctcct gaagctcatt
301 gagcaccccc acgtcctaaa gctgcacgac gtttatgaaa acaaaaaata tttgtacctg
361 gtgctagaac acgtgtcagg tggtagctc ttcgactacc tgggtgaaga ggggaggctg
421 acgcctaagg aggtcggaa gttcttccgg cagatcatct ctgcgctgga cttctgccac
481 agccactcca tatgccacag ggatctgaaa cctgaaaacc tcctgctgga cgagaagaac
541 aacatccgca tcgcagactt tggcatggcg tcctgacgag ttggcgacag cctgttggag
601 accagctgtg ggtcccccca ctacgcctgc cccgaggtga tccgggggga gaagtatgac
661 cgccggaagg cggacgtgtg gagctgcggc gtcatcctgt tcgccttgcg ggtgggggct
721 ttgcctctcg acgatgacaa cttgcgacag ctgctggaga aggtgaagcg gggcggttc
781 cacatgccgc actttatccc gcccgactgc cagagtctgc tacggggcat gatcgaggtg
841 gacgccgcac gccgcctcac gctagagcac attcagaaac acatatggta tatagggggc
901 aagaatgagc ccgaaccaga gcagccgatt cctcgcaagg tgcagatccg ctgcgtgccc
961 agcctggagg acatcgaccc cgacgtgctg gacagcatgc actcactggg ctgcttccga
1021 gaccgcaaca agctgctgca ggacctgctg tccgaggagg agaaccagga gaagatgatt
1081 tacttctctc tcctggaccg gaaagaaagg tacccgagcc aggaggatga ggacctgccc
1141 ccccggaacg agatagaccc tccccggaag cgtgtggact ccccgatgct gaaccggcac
1201 ggcaagcggc ggccagaacg caaatccatg gaggtgctca gcgtgacgga cggcggtcc
1261 ccggtgcctg cgcgcggggc cattgagatg gccagcacg gccagaggtc tcggtccatc
1321 agcgggtgct cctcaggcct ttccaccagc ccactcagca gccccgggt gaccctcac
1381 ccctaccaa ggggcagtcc cctccccacc cccaagggga cacctgtcca cagccaaag
1441 gagagcccgg ctggcacgcc caaccccacg ccccgctcca gccccagcgt cggaggggtg
1501 ccctggaggg cgcggtcaa ctccatcaag aacagctttc tgggtcacc ccgcttccac
1561 cgccggaac tgcaagttcc gacgccggag gagatgtcca acctgacacc agagtctcc
1621 ccagagctgg cgaagaagtc ctggtttggg aacttcatca gcctggagaa ggaggagcag
1681 atcttcgtgg tcatcaaaga caaacctctg agctccatca aggtgacat cgtgcacgcc

```

Certificate of Analysis

```
1741 ttccctgtcga ttcccagttct cagccacagc gtcattctccc aaacgagctt ccgggcccagag
1801 tacaaggcca cggggggggcc agccgtgttc cagaagccgg tcaagttcca gggtgatata
1861 acctacacgg aggggtgggga ggcgcagaag gagaacggca tctactccgt caccttcacc
1921 ctgctctcag gccccagccg tcgcttcaag aggggtggtgg agaccatcca ggcccagctg
1981 ctgagcacac acgaccgcc tgcggcccag cacttgtcag aaaaaaaaa accagcgcca
2041 ggactaagct ggggtgctgg gcttaagggc cagaaggtgg ccaccagcta cgagagtagc
2101 ctctga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services.